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a  b  s  t  r  a  c  t
The  study  of  the human  immune  response  to hepatitis  B  virus  (HBV)  has  been  hampered  by  the lack  of
an  adequate  model  to  evaluate  the  hepatitis  B surface  antigen  (HBsAg)  speciﬁc  cell  response.  Thus,  this
study  was  conducted  to  perform  an  in  vitro  analysis  of the  antigenic  properties  of  recombinant  HBsAg
and  demonstrate  the  inﬂuence  of  variables  such  as  culture  time,  antigen  concentration  and  cell  density
on  lymphocyte  proliferation.  Peripheral  blood  mononuclear  cells (PBMCs)  were  isolated  from  the  venouseywords:
ecombinant HBV surface antigen
n vitro cellular response
BV vaccine
blood  of  vaccinated  individuals,  and  in vitro  cellular  immune  responses  were  evaluated  using  an  HBsAg-
speciﬁc  proliferation  assay.  Lymphoproliferative  responses  were  detected  in  culture  systems,  despite  the
lack of  serum  antibodies.  Optimal  results  were  obtained  when  lymphocytes  were stimulated  at  a  seeding
density of 4 ×  106 cells/mL,  with  50 ng/mL  of  recombinant  HBsAg  protein  vaccine  for  3  days.  Data  from
the  present  study  may  contribute  to the  development  of  an adequate  system  to  evaluate  the cellular
immune  responses  to HBsAg  in  vaccine  recipients.
© 2013 Elsevier B.V. All rights reserved.. Introduction
Since the introduction of hepatitis B virus (HBV) vaccina-
ion, many epidemiological investigations have been performed to
ssess long-term immunity against HBV infection. Several stud-
es have shown levels of hepatitis B surface antibody (anti-HBs)
elow 10 IU/L in vaccinated populations (Zanetti et al., 2005;
hongsrisawat et al., 2006; Lu et al., 2006; Voigt et al., 2010;
ivramento et al., 2011; Tonial et al., 2011; Scaraveli et al., 2011;
assos et al., 2011). Nevertheless, the need for booster doses
gainst hepatitis B in individuals with anti-HBs less than 10 IU/L
as still to be determined (Kane et al., 2000; Poorolajal et al.,
010).
∗ Corresponding author at: Department of Clinical Analysis, Health Sciences Cen-
er, Federal University of Santa, Catarina, University Campus, Florianópolis, Santa
atarina 88040-900, Brazil. Tel.: +55 48 3721 9712; fax: +55 48 3721 9542.
E-mail address: celso@ccs.ufsc.br (C. Spada).
166-0934/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.jviromet.2013.07.043The role of humoral and cell-mediated immunity against hepati-
tis surface B antigen (HBsAg) is a complex mechanism. In many viral
diseases, elimination of the virus depends on intact cell-mediated
immunity. This may  also be important in the case of hepatitis B
(Dudley et al., 1972). Furthermore, the correlation between the out-
come of in vitro T-cell responses and the in vivo antibody production
provides direct evidence for the hypothesis that the variability of
the B-cell responses reﬂects the variability of the T-cell response
(Leroux-Roels et al., 1994).
However, a major obstacle to the study of the human immune
response to HBsAg has been the lack of an adequate model to mon-
itor the HBsAg-speciﬁc T-cell response. The lack of an efﬁcient
cell culture system may  have seriously held back progress in HBV
research (Guha et al., 2004). The assessment of hepatitis B vaccine
efﬁcacy is based mainly on the measurements of serum antibody
levels through immunoenzymatic methods (Liu et al., 2011). Thus,
this study was  conducted to perform an in vitro analysis of the anti-
genic properties of recombinant HBs antigen and demonstrate the
inﬂuence of variables such as culture time, antigen concentration
irological Methods 193 (2013) 572– 578 573
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Table 1
Anti-HBs titers.
Donor Sex Age (years) Serum anti-HBs (IU/L)
Seropositive
1 M 15 2.2
2  F 61 6.8
3  F 22 8.8
4  F 65 9.0
5  M 14 10.0
6  F 19 15.2
7  F 27 38.2
8  F 29 51.2
9  M 57 217.1
10  M 22 551.8
Seronegative
1  M 14 Undetectable
2  M 15 Undetectable
3  F 16 Undetectable
4  F 18 UndetectableA. do Livramento et al. / Journal of V
nd cell density on lymphocyte proliferation in vaccinated individ-
als.
. Methods
.1. Lymphocyte donors
HBs antigen speciﬁc proliferative responses were analyzed in
ealthy volunteers who  had received the standard three-dose
epatitis B vaccine schedule, according to vaccination cards. Ten
accinated individuals who were seropositive for anti-HBs (six
emales and four males aged 14–65 years) and ﬁve seronegative
accinees (three females and two males aged 14–47 years) were
elected for the survey.
This study was approved by the Ethics Committee of the Federal
niversity of Santa Catarina (Protocol 1000/2010), and approved by
he Health Secretary of Blumenau, Santa Catarina, Brazil. Informed
ritten consent was obtained from all participants or a responsible
uardian.
.2. Anti-HBs titers
A blood sample was collected from each subject to measure the
oncentration of antibodies to hepatitis B virus surface antigen.
fter separation of the serum, anti-HBs antibodies were deter-
ined by an enzyme-linked immunosorbent assay (ELISA) using a
ommercially available kit (Biokit, Barcelona, Spain), according to
he manufacturer’s instructions. Bioelisa anti-HBs is a direct immu-
oenzymatic method of the sandwich type in which the samples to
e analyzed are incubated in wells of a microplate that are coated
ith highly puriﬁed HBsAg. If a sample contains anti-HBs, they
ill bind speciﬁcally to the HBsAg in the well. After washing to
emove the residual sample, HBsAg conjugated to peroxidase is
dded and binds to the antigen–antibody complex that formed dur-
ng the ﬁrst incubation. After this second incubation and washing,
n enzyme substrate containing a chromogen is added. This solu-
ion will develop a blue color if the sample contains anti-HBs. The
lue color changes to yellow after blocking the reaction with sulfu-
ic acid. The intensity of color is proportional to the concentration
f anti-HBs present in the test preparation.
.3. Lymphocyte proliferation assay
Peripheral blood mononuclear cells (PBMCs) were puriﬁed from
eparinized venous blood through Ficoll-Hypaque density gradient
entrifugation (Sigma–Aldrich, St. Louis, MO,  USA). Blood samples
ere collected just before the experiment. Cells were suspended in
ulbecco’s Modiﬁed Eagle’s Medium (DMEM, Gibco, Grand Island,
Y, USA) supplemented with 10% fetal bovine serum, 200 mM l-
lutamine, 10 mM HEPES, 110 mg/mL  sodium pyruvate, 50 U/mL
enicillin and 50 g/mL streptomycin. PBMCs (4 × 105 cells/mL and
 × 106 cells/mL) were seeded into 96-well cell culture plates in
he presence of HBsAg (50 ng/mL, 100 ng/mL, 300 ng/mL, 1.0 g/mL
nd 1.5 g/mL) for 3 days, 7 days and 14 days at 37 ◦C in an atmo-
phere of 5% CO2 in air. Phytohemagglutinin (PHA, Gibco, Grand
sland, NY, USA) at 1% (v/v) was used as positive control to stim-
late lymphocyte proliferation. As negative control cultures, cells
ere incubated in supplemented DMEM without antigen stimula-
ion (Wang et al., 2004; Prasad et al., 2008; Oshima et al., 2011).
Cell proliferation was assessed by a colorimetric 3-(4,5-
imethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
ssay (Invitrogen, Carlsbad, CA, USA). The MTT  assay was performed
sing the method described by Mosmann (1983). Four hours before
he end of the assay, 10 L of 5 mg/mL  MTT  was added to each well.
he reaction was ended by adding 100 L of dimethylsulfoxide
DMSO) to induce the dissolution of formazan crystals. The optical5  F 47 Undetectable
Abbreviations: F, female; M,  male.
density (OD) of the developed color was read on a microplate reader
(Anthos 2020, Anthos Labtec Instruments, Wals, Austria) at 570 nm.
The results of the lymphocyte proliferation assay are presented as
the proliferation index (PI) [PI = 100 × (OD stimulated culture − OD
negative control culture)/OD negative control culture] (Risco et al.,
2003; Manosroi et al., 2003).
2.4. In vitro cell stimulation
PBMCs were stimulated in vitro with the recombinant HBsAg
vaccine VrHB-IB. VrHB-IB is a monovalent hepatitis B vaccine pro-
duced by the Butantan Institute (São Paulo, Brazil), a public sector
Brazilian vaccine manufacturer, and is provided at no cost in pub-
lic vaccination clinics. This vaccine contains puriﬁed particles of
HBsAg produced by recombinant yeast (Hansenula polymorpha),
and is formulated with 25 g/mL of recombinant antigen and alu-
minum hydroxide as the adjuvant (Luna et al., 2009; Moraes et al.,
2010).
2.5. Statistical analysis
T cell proliferation is represented as proliferation indices. Stu-
dent’s t-test or analysis of variance (ANOVA) and the Bonferroni
post hoc test were used to determine the statistical signiﬁcance
of differences between in vitro proliferation assays. Pearson linear
regression analysis was  used to assess the correlation between the
age of the subjects and lymphocyte proliferation indices. All statis-
tical analyses were performed using SPSS 17.0 software (SPSS Inc.,
Chicago, IL, EUA). In all statistical comparisons, p < 0.05 was taken
to indicate a signiﬁcant difference.
3. Results
The anti-HBs levels of the two  groups are displayed in Table 1.
The cell proliferative responses of vaccinated participants with
detectable anti-HBs titers to different doses of HBsAg and PHA are
shown in Figs. 1 and 2. The lymphocyte proliferative response to
1% PHA was  lower than that of HBsAg.
The mean responses to HBsAg observed with both cell densities
were signiﬁcantly higher after 3 days of culture than after 7 days
and 14 days (p < 0.001), with less variability between samples. After
3 days of stimulation, there was no signiﬁcant difference (p > 0.05)
between the different doses of HBsAg at both cell densities. How-
ever, after 7 days and 14 days of culture, the PI to 50 ng/mL HBsAg
was signiﬁcantly higher compared to the other doses (Fig. 3).
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Fig. 1. Lymphoproliferative responses (PI) of the group with detectable anti-HBs. Cell density of 4 × 105 cells/mL stimulated with different doses of HBsAg and 1% PHA for 3
days  (A), 7 days (B) and 14 days (C).
Table 2
Lymphocyte proliferation to HBsAg and PHA in the group with detectable anti-HBs.
HBsAg % lymphocyte proliferation (mean and conﬁdence interval)
4 × 105 cells/mL 4 × 106 cells/mL
3 days CI 95% 7 days CI 95% 14 days CI 95% 3 days CI 95% 7 days CI 95% 14 days CI 95%
50 ng/mL 74.7 69.3–80.1 41.5a* 28.5 to 54.6 41.0a** 21.2 to 60.9 87.6b 77.0–98.1 51.3a** 44.0–58.6 47.4a** 34.7 to 60.0
100  ng/mL 71.6 65.2–78.0 32.4 18.9 to 45.8 9.7 −3.1 to 22.5 85.5 73.1–97.9 40.2 32.3–48.2 10.9 1.9 to 19.9
300  ng/mL 69.6 61.9–77.4 29.8 18.9 to 40.7 −0.3 −11.6 to 11.0 86.8 74.8–98.9 40.7 29.9–51.5 2.0 −8.0 to 12.0
1.0  g/mL 71.1 64.7–77.6 33.4 19.7 to 47.1 1.7 −10.1 to 13.6 85.5 74.5–96.5 34.7 27.3–42.0 −4.8 −17.9 to 8.4
1.5  g/mL 69.6 65.3–74.0 38.3 26.4 to 50.2 9.5 −3.9 to 23.0 82.8 70.1–95.6 35.1 26.3–44.0 5.9 −6.4 to 18.2
PHA  8.4 5.6–11.2 2.7 −1.4 to 6.8 −32.2 −43.0 to −21.4 16.4 1.9–30.8 10.1 0.01–20.2 −38.7 −43.1 to −34.2
a Comparison of PI to different doses of HBsAg:*p < 0.01 **p < 0.001.
b Comparison of the mean PI to different doses of HBsAg between the two cell densities at day 3: p < 0.001.
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cig. 2. Lymphoproliferative responses (PI) of the group with detectable anti-HBs. C
ays  (A), 7 days (B) and 14 days (C).
Cells cultured at a concentration of 4 × 106 cells/mL showed
igher mean proliferation responses to HBsAg compared to the
ell seeding density of 4 × 105 cells/mL at day 3 (p < 0.001). Never-
heless, there was no signiﬁcant difference (p > 0.05) between the
ymphoproliferative responses to PHA. The responses to the same
oses of HBsAg did not differ signiﬁcantly (p > 0.05) between the cell
ensities after 7 days and 14 days of culture (Table 2). There was
o statistical difference in the responses between vaccinees with
erum anti-HBs levels <10 IU/L and those with serum anti-HBs lev-
ls ≥10 IU/L. Also, linear regression analysis showed that there was
ot a signiﬁcant correlation between the age of the subjects and
n vitro lymphocyte proliferation response (Fig. 4).
Under the optimal conditions for lymphocyte proliferation, the
esponse to HBsAg was evaluated in vaccinated individuals who
ere seronegative for anti-HBs. All subjects with undetectable anti-
odies showed HBsAg-speciﬁc cell proliferation. When the PI to
0 ng/mL and 1.0 g/mL of HBsAg cultured at 4 × 106 cells/mL for days were compared, there was no statistically signiﬁcant differ-
nce between the anti-HBs negative and positive groups. However,
he lowest proliferative responses to HBsAg were observed in vac-
inated subjects with undetectable anti-HBs levels. On the othersity of 4 × 106 cells/mL stimulated with different doses of HBsAg and 1% PHA for 3
hand, among the seronegative individuals, the lymphoproliferative
response toward PHA was  comparable to the seropositive group
(17.8 ± 7.1 vs. 16.4 ± 19.1 p > 0.05) (Fig. 5).
4. Discussion
In lymphocyte cultures, both B- and T-lymphocytes are stimu-
lated by antigens, but mainly T-lymphocytes are activated (Roitt
et al., 1969; Vischer, 1972). The T-cell response to the HBV vacci-
nation has not been entirely characterized. Recombinant HBsAg,
HBsAg adjuvanted vaccine, puriﬁed HBsAg, preS1, preS2 and
peptides of HBsAg have been used to stimulate the lymphocyte pro-
liferative response in vitro (De Gast et al., 1973; Fernan et al., 1989;
Ferrari et al., 1989; Cupps et al., 1993; Wang et al., 2004; Desombere
et al., 2005; Vandepapelière et al., 2008; Carollo et al., 2013). How-
ever, despite the availability of highly puriﬁed plasma-derived or
recombinant HBsAg of pharmaceutical quality, the progress in lym-
phocyte culture techniques and the advent and widespread use of
an HBsAg vaccine, the development of a lymphoproliferative assay
has been a difﬁcult procedure (Leroux-Roels et al., 1994).
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sig. 3. Mean lymphoproliferative responses (PI) of the group with detectable
nti-HBs to different doses of HBsAg. Cell density of 4 × 105 cells/mL (A) and
 × 106 cells/mL (B) stimulated with HBsAg for 3, 7 and 14 days.
The MTT  assay was used in this study to determine lymphocyte
roliferation. The MTT  assay has been demonstrated to produce
omparable results with the tritiated thymidine method, and this
ethod also avoids exposure to radioactive material (Keck and
odine, 2006; Verma et al., 2010; Rana et al., 2011).
In the present study, the recombinant HBsAg protein vaccine
timulated the in vitro proliferation of lymphocytes from vac-
inated individuals. Immune responses against HBsAg could be
etected in the culture system despite the low levels of serum anti-
Bs. In a previous in vitro proliferative assay carried out in patients
ith chronic hepatitis and patients recently recovered from acute
ig. 4. Mean lymphoproliferative responses (PI) of the group with detectable anti-HBs to d
timulated for 3 days (A), 7 days (B) and 14 days (C). Cell density of 4 × 106 cells/mL stimuical Methods 193 (2013) 572– 578
hepatitis B, there were no lymphoproliferative responses to HBsAg.
Cells cultured in the presence of HBsAg usually incorporated less
than 20% and in no case incorporated greater than 20% more
3H-thymidine than lymphocytes cultured without HBsAg (Hanson
et al., 1984). Fernan et al. (1989) were unable to detect HBsAg-
speciﬁc proliferation in any of the subject groups studied, despite
the use of a range of antigen concentrations, cell ratios and cul-
ture periods. Peripheral blood T cells (1 × 105) were cultured with
1 × 104 autologous monocytes as antigen-presenting cells (APCs).
On the other hand, some studies have reported the successful detec-
tion of proliferative lymphocyte responses to HBsAg in vitro (De
Gast et al., 1973; Leroux-Roels et al., 1994; Wang et al., 2004;
Desombere et al., 2005; Vandepapelière et al., 2008; Nyström et al.,
2008; Bes et al., 2012; Carollo et al., 2013).
In the present study, cells cultured for 3 days gave the max-
imal stimulation and the lowest variability among the samples.
The proliferation index at day 7 and day 14 showed a statistically
signiﬁcant decrease, reaching cytotoxic effects after 14 days of cul-
ture. This study also demonstrates that cell seeding at a density of
4 × 106 cells/mL (4 × 105 cells/well) for 3 days showed maximum
responses to HBsAg. Furthermore, lymphoproliferative responses
in the range of 50 ng/mL to 1.5 g/mL of HBsAg did not differ after
3 days of stimulation, but after 7 and 14 days the PI to 50 ng/mL
was signiﬁcantly higher.
Wang et al. (2004) observed that 1.0 g/mL HBsAg, with
4 × 105 cells/well, the use of human AB+ serum and 6 days of
culture achieved optimal results for a T lymphocyte proliferative
response. These results are in agreement with previously described
assay conditions (Leroux-Roels et al., 1994). In another report,
300,000 lymphocytes were cultured in 12–75 mm  Falcon tubes in
1 mL  of MEM-Eagle medium. In most cases, maximum stimula-
tion by puriﬁed heat-inactivated HBsAg was found with 10 g/mL,
but in some cases it was with 50 g/mL (De Gast et al., 1973).
Vandepapelière et al. (2008) stimulated 2 × 105 PBMCs/well with
0.1, 1.0 and 10.0 g/mL of HBs antigen for 4 days. The lymphopro-
liferative response increased with the dose of stimulating antigen,
from 18.68 to 28.09 and 52.27 after stimulation with 0.1, 1.0 and
10 g/mL, respectively.
ifferent doses of HBsAg according to the subject’s age. Cell density of 4 × 105 cells/mL
lated for 3 days (D), 7 days (E) and 14 days (F).
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There are several explanations for the differences in the results
f in vitro lymphocyte proliferation studies. These include vari-
bles such as the geometry of the wells, the quality of culture
edia and the added serum, the antigen preparation method used
nd its purity, the techniques used to isolate lymphocytes and the
onditions of the in vitro assay (Hanson et al., 1984; Wang et al.,
004). The stage of differentiation, response to growth factors and
ytokines, as well as the response to apoptosis signals may  inﬂu-
nce the survival of lymphocytes from peripheral blood in culture
ssays (Belmonte et al., 2009). Furthermore, the difﬁculty in induc-
ng HBsAg-speciﬁc proliferative responses in cultures of fresh PBMC
s most probably due to the low frequency of HBsAg-speciﬁc cells
n circulation (Leroux-Roels et al., 1994).
Although the lowest proliferative indexes in this study were
ound in vaccinated subjects with undetectable anti-HBs levels,
o statistical difference was observed between the lymphopro-
iferative responses of the seropositive and seronegative groups.
owever, the lowest speciﬁc proliferative peaks in this group sug-
est a higher frequency of HBs memory cells in vaccinated subjects
ith detectable anti-HBs.
In conclusion, lymphoproliferative responses to recombinant
BsAg protein vaccine were detected in a culture system, despite
ow levels of serum anti-HBs. In addition, data from this study
howed that 50 ng/mL of HBsAg, 4 × 106 cells/mL and 3 days of cul-
ure provided the optimal results. The outcomes from the present
tudy may  be a useful tool for the development of an adequate
ystem to monitor the HBsAg-speciﬁc cell response. Such studies
ay  help with forthcoming decisions on hepatitis B vaccine booster
oses to maintain anti-HBs levels higher than 10 IU/L.
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